Navigation Links
ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica

Partnership will add new technology to help ORBIS train doctors in the treatment of retinal disorders

NEW YORK, Jan. 26 /PRNewswire-USNewswire/ -- ORBIS International, a nonprofit organization dedicated to saving sight worldwide, has received a donated PASCAL photocoagulator as part of a new partnership with global ophthalmic company OptiMedica Corp. Used to treat a variety of retinal diseases, PASCAL dramatically improves the physician's ability to control the precision, safety and efficiency of the photocoagulation procedure, while minimizing treatment duration, treatment frequency and patient discomfort.

"We are incredibly thankful to OptiMedica for their generous donation. The addition of the PASCAL to the ORBIS Flying Eye Hospital will greatly enhance our technical capabilities to treat diabetic retinopathy, which is rapidly affecting a growing number of individuals around the world," said ORBIS Medical Director Hunter Cherwek, M.D.

At least 171 million people have diabetes, and this figure is likely to more than double by the year 2030, to 366 million. After 15 years, about 2 percent of persons with diabetes become blind and about 10 percent develop severe visual loss. After 20 years, more than 75 percent of patients will have some form of diabetic retinopathy, a complication of diabetes that results from damage to the blood vessels of the light-sensitive tissue at the back of the eye, according to the World Health Organization.

Laotians first to benefit from ORBIS and OptiMedica partnership

The Flying Eye Hospital -- a DC-10 aircraft converted into a mobile ophthalmic surgical unit -- has begun the year in Laos, a country ORBIS has never before visited. Through the transfer of knowledge and skills, the Flying Eye Hospital program currently underway in Vientiane, Laos is strengthening the ability of eye health professionals in the management and prevention of eye diseases. Diabetic patients selected for treatment during the January 19-30 program are the first to benefit from ORBIS' use of the PASCAL Method of photocoagulation.

"OptiMedica is very proud to make this donation to the ORBIS Flying Eye Hospital because we strongly believe that the patients they treat and the physicians they train will benefit greatly from the significant advancements inherent in PASCAL technology," said Mark J. Forchette, president and chief executive officer of OptiMedica. "Using PASCAL as part of this unique initiative, ORBIS will allow doctors from Laos and many other countries around the world to set a new standard in the treatment of diabetic retinopathy and other retinal diseases. We believe that the gains in treatment efficiency and patient comfort made possible with PASCAL will have a profound impact in the regions served by the Flying Eye Hospital."

ORBIS retains a global cadre of more than 500 volunteer doctors who donate their time for one- or two-week periods to work with the Flying Eye Hospital team. Joining ORBIS in Vientiane will be first-time volunteer Julia Haller, M.D., Ophthalmologist-in-Chief at Wills Eye Hospital, Professor and Chair of Ophthalmology, Thomas Jefferson University, Philadelphia, Pennsylvania, and an advisor to OptiMedica in the early stages of PASCAL development. Working alongside the ORBIS medical team, Dr. Haller will instruct Laotian doctors in the diagnosis and treatment of diabetic retinopathy and other retinal disorders. An OptiMedica engineer will also attend the program to coach ORBIS staff ophthalmologists and biomedical engineers in the proper use and maintenance of PASCAL.

ORBIS program offers many their first chance for continuing medical education

Laos' 25 eye doctors provide services to the nation's 6 million people. With more than 30,000 people blind, the Laotian Ministry of Health has acknowledged human resources as the key impediment to solving the country's problem of avoidable blindness, which is defined as blindness that could have been treated or prevented by known cost-effective means. Currently, there are no in-country subspecialty training programs for ophthalmologists, ophthalmic nurses or biomedical engineers.

Through the Flying Eye Hospital program, all 25 of the nation's eye care providers are attending ophthalmic training sessions on board the aircraft and at the Vientiane Ophthalmology Centre, the national coordinating body for eye care services. To expand ORBIS' impact and reach, 20 ophthalmologists from Thailand, Cambodia, Myanmar and Vietnam are joining the program and benefiting from training in the clinical diagnosis of eye diseases, surgical decision-making, incision/laser surgeries and post-operative care.

The Flying Eye Hospital serves as a focal point for ORBIS' educational programs and advocacy efforts. On board, eye care professionals from developing nations work side-by-side with the ORBIS medical team and volunteer teaching faculty to perform surgery, learn new skills and restore sight.

About ORBIS International

ORBIS International is a nonprofit global development organization dedicated to saving sight worldwide. Since 1982, ORBIS programs have benefited people in 86 countries, enhancing the skills of more than 195,000 health care personnel and providing eye care treatment for more than 6.8 million people. To learn more about ORBIS, please visit

About OptiMedica

Based in Santa Clara, Calif., OptiMedica Corp. is a global ophthalmic company dedicated to advancing the practice of ophthalmology for the benefit of physicians and their patients. The company holds the exclusive license to the PASCAL Photocoagulator technology, which was originally developed at Stanford University. Since its market introduction in 2006, PASCAL photocoagulation procedures have been performed on more than one hundred thousands patients worldwide. OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit

SOURCE ORBIS International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orbis Education Expands Nursing Education Program to Glendale, California
2. From Jet Engines to Search Engines, ORBIS-FedEx-Indiana University Join Forces to Fight Unnecessary Childhood Blindness
3. ORBIS and its Global Sponsors Join Forces to Bring a Five-Week Sight-Saving Program to Vietnam
4. ORBIS Internationals Flying Eye Hospital Returns to Myanmar
5. ORBIS International Announces the Death of the Honorable Oliver Foot, President and Board Member
6. ORBIS and Alcon Team Up to Provide Eye Care Education to School Students
7. Saint Josephs Launches International College of Robotic Surgery
8. International Medical Corps and Agility Logistics Partner to Enhance Delivery of Humanitarian Relief
9. FRC Condemns President Obamas $441 Million Bailout of International Abortions
10. After Eight Years of Injustice, International Family Planning Funding is Restored
11. Moog Acquires Buffalo-Based Ethox International
Post Your Comments:
(Date:12/1/2015)... ... ... Hospital Tampa is the first health care provider in the region to offer the ... is a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult ... least 40 to 45 kg, or a BMI of at least 35 to 39.9 kg ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Dr. Paul Vitenas, ... Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician Practice ... best among the many elite aesthetic physicians honored by the industry publication. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Annual 2015 Golden Bridge Business Awards under the New Products and Services category ... web based sample management software that helps labs organize data and ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been awarded a fixed price per sprint agile development contract to support ... $34 million over five years, provides software engineering, infrastructure, as well as operations ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015  Following an ... (NASDAQ: OGXI ) announced today that its Phase ... interim futility analysis of the intent-to-treat (ITT) population. In ... identified by the DMC. Both the DMC and OncoGenex ... expected in the second half of 2016, depending on ...
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology: